A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
NCT03412565
Completed
The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2025
Locations: Cancer Center of Central Connecticut - Southington, Southington, Connecticut +63 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
NCT01998971
Completed
The purpose of this study is to evaluate the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2025
Locations: Not set, Duarte, California +21 locations
Conditions: Multiple Myeloma
Register for Updates
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03150693
Suspended
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
03/28/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +458 locations
Conditions: B Acute Lymphoblastic Leukemia
Register for Updates
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
NCT03871829
Terminated
The purpose of this study is to compare the efficacy (rate of very good partial response \[VGPR\] or better as best response as defined by the International Myeloma Working Group \[IMWG\] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab to evaluate daratumumab retreatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +107 locations
Conditions: Multiple Myeloma
Register for Updates
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
NCT05303792
Active Not Recruiting
This phase II trial compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a drug, called CalichDMH. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers CalichDMH to kill them.... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/28/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +71 locations
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Register for Updates
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
NCT05224089
Recruiting
This study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (Exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (TAP) blocks for patients undergoing laparoscopic colectomy procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Bowel Disease
Register for Updates
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
NCT06232044
Not Yet Recruiting
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Multiple myeloma is a cancer that affects white blood cells called plasma cells, which are made in the bone marrow and are part of the immune system. Multiple myeloma cells have a prot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Mary Greeley Medical Center, Ames, Iowa +34 locations
Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
NCT05634369
Recruiting
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people with childhood sarcomas that have relapsed or not responded to prior therapies. The goals of this study are: * To determine the safety and efficacy of the addition of adoptive transfer of universal donor, TGFβ imprinted (TGFβi), expanded NK cells to the pediatr... Read More
Gender:
ALL
Ages:
Between 2 years and 40 years
Trial Updated:
03/28/2025
Locations: University of Alabama, South Birmingham, Alabama +15 locations
Conditions: Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
Register for Updates
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT04216524
Recruiting
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy work in different ways to stop the gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
Register for Updates
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
NCT05521087
Withdrawn
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring histone-lysine N-methyltransferase 2A1 (\[KMT2A1\], nucleophosmin 1 gene (NPM1), or nucleoporin alterations in Part 1 (Dose Escalation) and to further evaluate safety at the RP2D(s) of JNJ-75276617 in combination with chemotherapy in pediatric and young... Read More
Gender:
ALL
Ages:
Between 30 days and 30 years
Trial Updated:
03/28/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +10 locations
Conditions: Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia of Ambiguous Lineage
Register for Updates
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
NCT03578081
Completed
This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if olanzapine when given with other drugs, is still effec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +565 locations
Conditions: Malignant Neoplasm
Register for Updates
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
NCT01615029
Completed
The purpose of this study is to establish the safety profile of daratumumab when given in combination with Lenalidomide and dexamethasone in participants with relapsed or relapsed and refractory Multiple Myeloma (MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Not set, Boston, Massachusetts +7 locations
Conditions: Multiple Myeloma
Register for Updates